Arch Biopartners Inc.
ARCH.V
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -8.30% | 23.84% | |||
| Gross Profit | 134.62% | -907.14% | |||
| SG&A Expenses | -33.75% | 36.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.21% | 33.30% | |||
| Operating Income | 59.55% | -95.30% | |||
| Income Before Tax | 59.72% | -46.27% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 59.72% | -46.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 59.72% | -46.27% | |||
| EBIT | 59.55% | -95.30% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 60.61% | -43.48% | |||
| Normalized Basic EPS | 59.52% | -44.83% | |||
| EPS Diluted | 60.61% | -43.48% | |||
| Normalized Diluted EPS | 59.52% | -44.83% | |||
| Average Basic Shares Outstanding | 0.97% | 0.81% | |||
| Average Diluted Shares Outstanding | 0.97% | 0.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||